ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 ...
Researchers and supporters of the change said the old name, often shortened to PCOS, is inaccurate. It reduced a complex hormonal or endocrine disorder to a misunderstanding about cysts and a focus on ...